Rep. Jared Moskowitz Buys Stryker Co. (NYSE:SYK) Shares

Representative Jared Moskowitz (D-Florida) recently bought shares of Stryker Co. (NYSE:SYK). In a filing disclosed on May 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Stryker stock on April 7th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 4/16/2025.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 4/10/2025.
• Sold $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of Southern (NYSE:SO) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/7/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 4/7/2025.

Stryker Stock Performance

SYK stock opened at $387.97 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a 50 day moving average price of $365.31 and a 200 day moving average price of $374.73. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market capitalization of $148.08 billion, a PE ratio of 50.00, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. During the same quarter in the previous year, the company posted $2.50 EPS. Stryker’s revenue was up 11.9% on a year-over-year basis. Analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Elefante Mark B bought a new position in shares of Stryker during the fourth quarter worth approximately $337,000. Chicago Capital LLC increased its holdings in shares of Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after purchasing an additional 5,841 shares during the period. Zhang Financial LLC boosted its position in shares of Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Appleton Partners Inc. MA boosted its position in shares of Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after acquiring an additional 1,400 shares in the last quarter. Finally, Metis Global Partners LLC boosted its position in shares of Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after acquiring an additional 1,561 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Royal Bank of Canada upped their target price on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $427.05.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.